Sino-Argi Leading Biosciences (603970) — Capital Reinvestment Ratio
Latest as of December 2024:
0.00x
Sino-Argi Leading Biosciences (603970) has a Capital Reinvestment Ratio of 0.00x as of December 2024, meaning it reinvests 0% of its operating cash flow (CN¥702.54 Million) in capital expenditures (CN¥139.59K). See 603970 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥702.54 Million
CNY
Capital Expenditures
CN¥139.59K
CNY
Data as of
Dec 2024
Most recent filing
Sino-Argi Leading Biosciences Capital Reinvestment Ratio (2012–2024)
This chart tracks Sino-Argi Leading Biosciences's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Sino-Argi Leading Biosciences (2012–2024)
Year-by-year Capital Reinvestment Ratio for Sino-Argi Leading Biosciences from 2012 to 2024. For live market cap and broader valuation context, see Sino-Argi Leading Biosciences market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.01x | CN¥307.40 Million | CN¥2.18 Million | ▲ +217.1% |
| 2022 | 0.00x | CN¥1.54 Billion | CN¥3.44 Million | ▼ -81.7% |
| 2021 | 0.01x | CN¥325.42 Million | CN¥3.99 Million | ▼ -71.2% |
| 2020 | 0.04x | CN¥352.12 Million | CN¥14.99 Million | ▲ +248.8% |
| 2019 | 0.01x | CN¥218.90 Million | CN¥2.67 Million | ▼ -91.1% |
| 2018 | 0.14x | CN¥65.69 Million | CN¥8.99 Million | ▲ +28.2% |
| 2017 | 0.11x | CN¥518.83 Million | CN¥55.39 Million | ▼ -55.9% |
| 2016 | 0.24x | CN¥152.22 Million | CN¥36.85 Million | ▲ +58.5% |
| 2014 | 0.15x | CN¥40.41 Million | CN¥6.17 Million | ▲ +862.2% |
| 2012 | 0.02x | CN¥109.43 Million | CN¥1.74 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow